<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879747</url>
  </required_header>
  <id_info>
    <org_study_id>NRA 6280003</org_study_id>
    <nct_id>NCT02879747</nct_id>
  </id_info>
  <brief_title>Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children</brief_title>
  <acronym>MAINTENANCE</acronym>
  <official_title>Individualizing the Dose of Growth Hormone (GH) to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children Within TR 98-0198-003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective was to study whether normal growth velocity can be maintained with adapted GH
      dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled
      catch up growth (=difference to target height reached, less than - 0.6 SDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the trial is to study the effect of adapted GH treatment in order to find an
      individualized GH dose maintaining normal growth velocity close to target height SDS and
      normal metabolism after fulfilled catch up growth in prepubertal children treated with
      individual doses of GH within the trial 98-0198-003 (1). The overall aim is to find for the
      individual the lowest effective GH dose during maintenance period, maintaining normal growth
      velocity and metabolism, i.e. a satisfactory biological active dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2003</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Children Maintaining Normal Growth Velocity</measure>
    <time_frame>twelve months</time_frame>
    <description>The proportion of children in the intervention 1 group (=reduced dose) that maintained an individual ΔheightSDS within ±0.3 during the first year of the Maintenance trial, compared to the proportion of children in the intervention 2 group (non-reduced dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGF-I</measure>
    <time_frame>start of study to two years after start in the trial</time_frame>
    <description>Delta Insulin-like growth factor-I (24 months after start compared to start of study) expressed as ng/ml and converted to standard deviation scores (SDS) to adjust for gender and age.
A standard deviation score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A mean value within +-0.5 SDS and a range within +-1.0 SDS is a favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height SDS at Start of Puberty</measure>
    <time_frame>1-7 years in the trial</time_frame>
    <description>Height at start of puberty measured as cm and expressed as standard deviation score (SDS) to adjust for age and gender</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Height</measure>
    <time_frame>start of study to two years after start in the trial</time_frame>
    <description>Changes in height standard deviation scores (SDS) (calculated as height in cm at start converted to SDS and height in cm after two years in the trial converted to SDS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Short Stature</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unchanged dose Genotropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>reduced dose 50% Genotropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotropin</intervention_name>
    <description>Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth</description>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_label>Interventional 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participated in the 'GH-dose catch-up study' 98- 0198-003.

          -  Midparental height reached (difference less than 0.6 SDS)

          -  Prepubertal at start of the study (girls =B 1, boys: testes :&lt;; 3ml).

          -  Signed written informed consent from the patient's parents (and the child if old
             enough)

        Exclusion Criteria:

          -  Disease affecting growth other than correctly treated hypothyroidism.

          -  Incapable of following the study protocol (i.e. bad compliance in the previous study).

          -  Puberty (&gt; breast stage 2, or testes &gt; 4ml).

          -  Poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berit Kriström, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils-Östen Nilsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Halmstad Department of Pediatrics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Halldin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sten Ivarsson, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malmö Academic Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kerstin Albertsson-Wikland, MD, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gothenburg University, Departments of pediatrics</affiliation>
  </overall_official>
  <reference>
    <citation>Wikland KA, Kriström B, Rosberg S, Svensson B, Nierop AF. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res. 2000 Oct;48(4):475-84.</citation>
    <PMID>11004238</PMID>
  </reference>
  <results_reference>
    <citation>Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009 Feb;94(2):483-90. doi: 10.1210/jc.2008-1503. Epub 2008 Nov 11.</citation>
    <PMID>19001519</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <results_first_submitted>November 21, 2018</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment</keyword>
  <keyword>growth hormone</keyword>
  <keyword>childhood</keyword>
  <keyword>short stature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.gpgrc.gu.se</doc_url>
      <doc_comment>The document will be found under &quot;Trials&quot; and then &quot;GH-dose/Maintenance study&quot;</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://www.gpgrc.gu.se</doc_url>
      <doc_comment>The document will be found under &quot;Trials&quot; and then &quot;GH-dose/Maintenance study&quot;</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All children in the fix dose group and children in the individualized dose group who have reached their midparental height SDS (&gt;- 0.6 SDS) during at least two years of GH-treatment within the ‘GH-dose-catch up’ study (TR 98-0198-003) and still are prepubertal were eligible in the study.</recruitment_details>
      <pre_assignment_details>If glucose levels at the day of inclusion were higher than 7.1 mmol/L, then the child was excluded before assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Decreased GH Dose</title>
          <description>Decreased GH dose Genotropin
Genotropin: Children were randomized to 50% GH dose after 2-3 years of initial GH treatment in previous trial (years depending on achieved Catch-up)</description>
        </group>
        <group group_id="P2">
          <title>Unchanged GH Dose</title>
          <description>Unchanged GH dose
Genotropin: Children were randomized to unchanged dose after 2-3 years of initial GH treatment in previous trial (years depending on achieved Catch-up)</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Control Group with informed consent but not randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>98 children participated with two randomized arms (n=27+38) and one control arm with conventional fixed GH treatment (n=33).</population>
      <group_list>
        <group group_id="B1">
          <title>Decreased GH Dose</title>
          <description>Reduced dose 50% Genotropin
Genotropin: Children were randomized to decreased GH dose by 50% after 2-3 years of Catch-up growth</description>
        </group>
        <group group_id="B2">
          <title>Unchanged GH Dose</title>
          <description>Unchanged dose Genotropin
Genotropin: Children were randomized to unchanged GH dose after 2-3 years of Catch-up growth</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Control Group randomized in the previous study to fix dose.
This group of children continued with fix dose in the current trial after signing informed consent.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.53" spread="1.51"/>
                    <measurement group_id="B2" value="8.52" spread="2.11"/>
                    <measurement group_id="B3" value="8.33" spread="1.78"/>
                    <measurement group_id="B4" value="8.52" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Children Maintaining Normal Growth Velocity</title>
        <description>The proportion of children in the intervention 1 group (=reduced dose) that maintained an individual ΔheightSDS within ±0.3 during the first year of the Maintenance trial, compared to the proportion of children in the intervention 2 group (non-reduced dose)</description>
        <time_frame>twelve months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Decreased GH Dose</title>
            <description>Decreased GH dose Genotropin
Genotropin: Children were randomized to 50% GH dose after 2-3 years of initial GH treatment in previous trial (years depending on achieved Catch-up)</description>
          </group>
          <group group_id="O2">
            <title>Interventional 2</title>
            <description>Unchanged GH dose
Genotropin: Children were randomized to unchanged dose after 2-3 years of initial GH treatment in previous trial (years depending on achieved Catch-up)</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group children with fix dose through the previous and current trial and with signed consent</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Children Maintaining Normal Growth Velocity</title>
          <description>The proportion of children in the intervention 1 group (=reduced dose) that maintained an individual ΔheightSDS within ±0.3 during the first year of the Maintenance trial, compared to the proportion of children in the intervention 2 group (non-reduced dose)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGF-I</title>
        <description>Delta Insulin-like growth factor-I (24 months after start compared to start of study) expressed as ng/ml and converted to standard deviation scores (SDS) to adjust for gender and age.
A standard deviation score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A mean value within +-0.5 SDS and a range within +-1.0 SDS is a favorable outcome.</description>
        <time_frame>start of study to two years after start in the trial</time_frame>
        <population>Drop outs due to puberty or adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>Unchanged Dose</title>
            <description>Unchanged dose Genotropin
Genotropin: Children were randomized to unchanged GH dose after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O2">
            <title>Reduced Dose</title>
            <description>reduced dose 50% Genotropin
Genotropin: Children were randomized to decreased GH dose by 50% after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group treated with fix dose GH according to previous and current trial, with signed informed consent</description>
          </group>
        </group_list>
        <measure>
          <title>IGF-I</title>
          <description>Delta Insulin-like growth factor-I (24 months after start compared to start of study) expressed as ng/ml and converted to standard deviation scores (SDS) to adjust for gender and age.
A standard deviation score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A mean value within +-0.5 SDS and a range within +-1.0 SDS is a favorable outcome.</description>
          <population>Drop outs due to puberty or adverse events</population>
          <units>standard deviation scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="1.14"/>
                    <measurement group_id="O2" value="0.58" spread="0.91"/>
                    <measurement group_id="O3" value="-0.06" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height SDS at Start of Puberty</title>
        <description>Height at start of puberty measured as cm and expressed as standard deviation score (SDS) to adjust for age and gender</description>
        <time_frame>1-7 years in the trial</time_frame>
        <population>All 98 Children were measured at start of puberty</population>
        <group_list>
          <group group_id="O1">
            <title>Decreased GH Dose</title>
            <description>Children were randomized to decreased GH dose by 50% after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O2">
            <title>Unchanged GH Dose</title>
            <description>Children were randomized to unchanged GH dose after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Randomized in the previous study to fix dose. This Group of Children continued with fix dose in the current trial</description>
          </group>
        </group_list>
        <measure>
          <title>Height SDS at Start of Puberty</title>
          <description>Height at start of puberty measured as cm and expressed as standard deviation score (SDS) to adjust for age and gender</description>
          <population>All 98 Children were measured at start of puberty</population>
          <units>standard deviation scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.02"/>
                    <measurement group_id="O2" value="-1.06" spread="0.84"/>
                    <measurement group_id="O3" value="-0.98" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Height</title>
        <description>Changes in height standard deviation scores (SDS) (calculated as height in cm at start converted to SDS and height in cm after two years in the trial converted to SDS)</description>
        <time_frame>start of study to two years after start in the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unchanged Dose</title>
            <description>Unchanged dose Genotropin
Genotropin: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O2">
            <title>Reduced Dose</title>
            <description>reduced dose 50% Genotropin
Genotropin: Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Control Group with fix dose throughout the previous and current trial. Signed informed consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Height</title>
          <description>Changes in height standard deviation scores (SDS) (calculated as height in cm at start converted to SDS and height in cm after two years in the trial converted to SDS)</description>
          <units>standard deviation scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.57" spread="0.36"/>
                    <measurement group_id="O3" value="0.55" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two years or in some cases up to seven prepubertal years</time_frame>
      <desc>No relevant information according to reviewer.</desc>
      <group_list>
        <group group_id="E1">
          <title>Decreased GH Dose</title>
          <description>Reduced dose 50% Genotropin Children were randomized to decreased GH dose by 50% after 2-3 years of Catch-up growth</description>
        </group>
        <group group_id="E2">
          <title>Unchanged GH Dose</title>
          <description>Unchanged dose
Children were randomized to unchanged dose after 2-3 years of Catch-up growth</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Control Group with fix dose.
Children that were randomized to fix dose in the previous and current trial and signed informed consent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Otitis media with perforation needed hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Hospitalization for risk of appendicitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>facial nerve palsy due to tick disease</sub_title>
                <description>Hospitalization due to need for intravenous antibiotic treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (upper)</sub_title>
                <description>Urinary tract infection with hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>accident</sub_title>
                <description>Hospitalization due to car accident</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <description>Fracture after falling from a tree</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>virosis</sub_title>
                <description>Common adverse event was virosis winter-time</description>
                <counts group_id="E1" events="52" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E2" events="46" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E3" events="53" subjects_affected="24" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jovanna Dahlgren, PI and director of Department of Pediatrics</name_or_title>
      <organization>Queen Silvia Children´s Hospital and University of Gothenburg</organization>
      <phone>+46702750233</phone>
      <email>jovanna.dahlgren@gu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

